Please Wait
Applying Filters...
menu
    • menu
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    Rupatadine Fumarate

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,234Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Name of the Firm Written Confirmation No. Product Name Issue Date Valid Till Address of the Firm
    17/05/2021 Cadila Pharmaceuticals
    India
    		 M/s. Cadila Pharmaceuticals Ltd., WC-0074 Rupatadin Fumarate EP 2022-09-01 2025-07-02 294, GIDC Estate, Ankleshwar-393 002, Bharuch, Gujarat, India
    18/05/2020 Cadila Pharmaceuticals
    India
    		 Cadila Pharmaceuticals WC-0074A1 Rupatadin Fumarate EP 2019-07-29 2022-07-02 294, GIDC Estate, Ankleshwar-393 002, Bharuch, Gujarat, India